Answers are grounded in this paper and cite their sources.
Although the supporting evidence for oncological benefits of therapeutic systemic agents with respect to metastatic sites is not yet strong enough to provide a recommendation in advanced or metastatic urothelial carcinoma, clinicians may take into account tumor organotropism only in discussion with the patient fully informed on the optimal treatment decision to be taken.
No takes yet. Share an insight, caveat, or question.
Parizi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: